Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 26;1:100008. doi: 10.1016/j.tru.2020.100008

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Thromboelastographic analysis of COVID-patients #1 and #2.

Compared to control (A), blood samples from COVID-19 patients #1 and #2 showed prolonged clotting time in Ex-Test (activation of the extrinsic coagulation pathway) due to the anticoagulation with heparin (B) and argatroban (C), respectively. Induction of fibrinolysis by tissue plasmin activator (TPA-test) caused an immediate resolution of the formed clot in control (D). In contrast, remarkable resistance and no complete clot lysis was observed in patient # 1 (E), while a delay of approximately 5 min was observed till complete clot lysis was obtained in patient # 2 (F).